271. 強直性脊椎炎 Ankylosing spondylitis Clinical trials / Disease details
臨床試験数 : 574 / 薬物数 : 359 - (DrugBank : 68) / 標的遺伝子数 : 41 - 標的パスウェイ数 : 146
Showing 1 to 10 of 70 diseases
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05379049 (ClinicalTrials.gov) | March 1, 2022 | 7/5/2022 | Therapeutic Response to Tumor Necrosis Factor-alpha (TNF-alpha) Antagonists in Rheumatoid Arthritis. Therapeutic Response to Tumor Necrosis Factor-alpha (TNF-alpha) Antagonists in Rheumatoid Arthritis. ... | Evaluation of the Therapeutic Response to TNF-alpha Antagonist (Etanercept, Infliximab, Adalimumab) in Patients With Rheumatoid Arthritis; Using Plasma TNF-alpha as a Competent Biomarker. Single Center Study in Sulaymaniyah/ Iraq Evaluation of the Therapeutic Response to TNF-alpha Antagonist (Etanercept, Infliximab, Adalimumab) ... | Rheumatoid Arthritis;Inflammatory Arthritis;Ankylosing Spondylitis | Biological: Infliximab: Adalimumab; Etanercept | University of Sulaimani | NULL | Recruiting | 18 Years | N/A | All | 80 | Iraq | |
2 | NCT05164198 (ClinicalTrials.gov) | January 15, 2022 | 8/11/2021 | Multicenter, Prospective Clinical Trial for Optimizing TNF Inhibitor Dose Adjustment in Ankylosing Spondylitis Patients With Stable Disease Activity Multicenter, Prospective Clinical Trial for Optimizing TNF Inhibitor Dose Adjustment in Ankylosing S ... | Multicenter, Prospective Clinical Trial for Optimizing TNF Inhibitor Dose Adjustment in Ankylosing Spondylitis Patients With Stable Disease Activity Multicenter, Prospective Clinical Trial for Optimizing TNF Inhibitor Dose Adjustment in Ankylosing S ... | Ankylosing Spondylitis;Axial Spondyloarthritis | Biological: Adalimumab and its biosimilars;Biological: Biological: Etanercept and its biosimilars;Biological: Golimumab;Biological: Infliximab biosimilar Biological: Adalimumaband its biosimilars;Biological: Biological: Etanerceptand its biosimilars;Biol ... | Hanyang University Seoul Hospital | Linical Korea | Not yet recruiting | 18 Years | 65 Years | All | 448 | Phase 4 | NULL |
3 | NCT04507763 (ClinicalTrials.gov) | August 1, 2020 | 27/7/2020 | Study To Evaluate The Impact Of Early Initiation Of Biological Treatment With Ankylosing Spondylitis Study To Evaluate The Impact Of Early Initiation Of Biological Treatment With Ankylosing Spondylitis ... | Clinical Outcomes of Early Versus Delayed Management of Iraqi Patients With Ankylosing Spondylitis (AS) With Etanercept Clinical Outcomes of Early Versus Delayed Management of Iraqi Patients With Ankylosing Spondylitis ( ... | Ankylosing Spondylitis | Drug: Etanercept | Pfizer | NULL | Completed | 18 Years | N/A | All | 1 | Iraq | |
4 | NCT04077957 (ClinicalTrials.gov) | October 7, 2019 | 1/9/2019 | Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs Treat-to-target Strategy in Ankylosing Spondylitis Using Etanerceptand Conventional Synthetic DMARDs ... | Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs, a Prospective Randomized Controlled Study Treat-to-target Strategy in Ankylosing Spondylitis Using Etanerceptand Conventional Synthetic DMARDs ... | Ankylosing Spondylitis;Spondyloarthritis | Drug: Methotrexate;Drug: Sulfasalazine;Drug: Hydroxychloroquine;Drug: Etanercept (50mg per week, for 4 weeks);Drug: Etanercept (50mg per week, for 2 weeks);Drug: Etanercept (50mg per week) Drug: Methotrexate;Drug: Sulfasalazine;Drug: Hydroxychloroquine;Drug: Etanercept(50mg per week, for ... | Nanfang Hospital of Southern Medical University | NULL | Not yet recruiting | 18 Years | 50 Years | All | 100 | Phase 4 | China |
5 | ChiCTR1900025749 | 2019-09-20 | 2019-09-07 | Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs, a Prospective Randomized Controlled Study Treat-to-target Strategy in Ankylosing Spondylitis Using Etanerceptand Conventional Synthetic DMARDs ... | Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs, a Prospective Randomized Controlled Study Treat-to-target Strategy in Ankylosing Spondylitis Using Etanerceptand Conventional Synthetic DMARDs ... | Ankylosing Spondylitis | Experimental:conventional synthetic Disease modifying anti-rheumatic drugs(csDMARDs);Experimental:Etanercept (Anbainuo 50mg per week, for 4 weeks);Experimental:Etanercept (Anbainuo 50mg per week, for 2 weeks);Positive Control:Etanercept (Anbainuo 50mg per week, for 12 weeks);Positive Control:Etanercept (Anbainuo 50mg per 10 days, for 12 weeks);Positive Control:Etanercept (Anbainuo 25mg per week, for 12 weeks);Positive Control:Etanercept (Anbainuo 25mg per 2 weeks, for 12 weeks); Experimental:conventional synthetic Disease modifying anti-rheumatic drugs(csDMARDs);Experimental:Et ... | Nanfang Hospital of Southern Medical University | NULL | Pending | 18 | 50 | Both | Experimental:50;Experimental:50;Experimental:50;Positive Control:50;Positive Control:50;Positive Control:50;Positive Control:50; | N/A | China |
6 | EUCTR2017-001970-41-DK (EUCTR) | 21/12/2017 | 15/09/2017 | Dose reduction and withdrawal of biological therapy in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: Protocol for a 18 months multi-centre trial Dose reduction and withdrawal of biological therapy in patients with rheumatoid arthritis, psoriatic ... | Dose reduction and discontinuation of biological therapy in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: Protocol for a 18 months randomised, open label, parallel-group, multi-centre trial - The BIODOPT trial (BIOlogical Dose OPTimisation) Dose reduction and discontinuation of biological therapy in patients with rheumatoid arthritis, psor ... | Rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis MedDRA version: 21.0;Level: LLT;Classification code 10040107;Term: Seropositive rheumatoid arthritis;System Organ Class: 100000004859 MedDRA version: 21.0;Classification code 10062719;Term: Seronegative rheumatoid arthritis;Classification code 10037160;Term: Psoriatic arthritis;System Organ Class: 100000004859 MedDRA version: 20.0;Classification code 10076297;Term: Non-radiographic axial spondyloarthritis;System Organ Class: 100000004859 MedDRA version: 21.1;Classification code 10041672;Term: Spondylitis ankylosing;Classification code 10002557;Term: Ankylosing spondylitis and other inflammatory spondylopathies;Classification code 10045966;Term: Unspecified inflammatory spondylopathy;System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis MedDRA version: 21.0;Level: LL ... | Trade Name: Orencia Product Name: Abatacept Product Code: L04AA24 INN or Proposed INN: ABATACEPT Trade Name: Orencia Product Name: Abatacept Product Code: L04AA24 INN or Proposed INN: ABATACEPT Trade Name: Humira Product Name: Adalimumab Product Code: L04AB04 INN or Proposed INN: ADALIMUMAB Trade Name: Cimzia Product Name: Certolizumab pegol Product Code: L04AB05 INN or Proposed INN: CERTOLIZUMAB PEGOL Trade Name: Enbrel Product Name: Etanercept Product Code: L04AB01 INN or Proposed INN: ETANERCEPT Trade Name: Orencia Product Name: Abatacept Product Code: L04AA24 INN or Proposed INN: ABATACEPT Trade N ... | MD, PhD Salome Kristensen | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 180 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ... | Denmark | ||
7 | NCT02809781 (ClinicalTrials.gov) | June 2016 | 16/6/2016 | A Pilot Study of MSCs Iufusion and Etanercept to Treat Ankylosing Spondylitis | Phase III Study of Human Bone Marrow-Derived Mesenchymal Stem Cells to Treat AS | Spondylitis;Spondylitis, Ankylosing;Ankylosis;Arthritis;Spondylarthritis;Spondylarthropathies;Spinal Diseases;Musculoskeletal Diseases;Bone Diseases Spondylitis;Spondylitis, Ankylosing;Ankylosis;Arthritis;Spondylarthritis;Spondylarthropathies;Spinal ... | Biological: Intravenous infusion of MSCs;Drug: Etanercept | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Nanfang Hospital of Southern Medical University;Second Affiliated Hospital of Guangzhou Medical University Nanfang Hospital of Southern Medical University;Second Affiliated Hospital of Guangzhou Medical Univ ... | Recruiting | 18 Years | 45 Years | Both | 250 | Phase 2/Phase 3 | China |
8 | NCT02638896 (ClinicalTrials.gov) | January 2016 | 20/12/2015 | Dose Reduction of Etanercept in Patients With Ankylosing Spondylitis | Efficacy and Safety of Etanercept Dose Reduction in Patients With Ankylosing Spondylitis | Ankylosing Spondylitis | Drug: etanercept (Half-Dose);Drug: etanercept (Full-Dose);Drug: Sulfasalazine;Drug: Celecoxib | Zhixiang Huang | NULL | Not yet recruiting | 18 Years | 45 Years | Both | 100 | Phase 4 | NULL |
9 | EUCTR2015-002284-42-FI (EUCTR) | 18/09/2015 | 28/08/2015 | The rationale for this study is to gain insight in the extent and impact of immunogenicityof TNF inhibitors in the European daily clinical practice. Furthermore, an European widedatabase will give insight in factors influencing immunogenicity and treatment outcomein terms of disease activit The rationale for this study is to gain insight in the extent and impact of immunogenicityof TNF inh ... | INTENT: immunogenicity in patients failing response on anti-TNF-Immunogenicity and pharmacokinetics in patients failing torespond to TNF inhibitors (phase 1);-Clinical effectiveness of subsequent TNF inhibitor treatment andpredictive value of pharmacokinetics and immunogenicity (phase2) - INTENT INTENT: immunogenicity in patients failing response on anti-TNF-Immunogenicity and pharmacokinetics ... | rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and psoriasis.;Therapeutic area: Not possible to specify rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and psoriasis.;Therapeutic area: N ... | Trade Name: Enbrel Product Name: etanercept Trade Name: Humira Product Name: adalimumab Trade Name: Cimzia Product Name: certolizumab pegol Trade Name: Simponi Product Name: golimumab Trade Name: Remicade Product Name: infliximab Trade Name: Enbrel Product Name: etanercept Trade Name: Humira Product Name: adalimumab Trade Name: Cimz ... | READE | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 1650 | Phase 1 | Finland | ||
10 | NCT01934933 (ClinicalTrials.gov) | September 24, 2014 | 17/8/2013 | Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis Etanerceptand Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Sp ... | A Multi-center, Open Label, Random Clinical Trial of Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis A Multi-center, Open Label, Random Clinical Trial of Etanerceptand Celecoxib Alone/Combined Treatmen ... | Ankylosing Spondylitis | Drug: celebrex;Drug: Enbrel;Drug: Enbrel plus Celebrex | Sun Yat-sen University | NULL | Completed | 18 Years | 65 Years | All | 150 | Phase 4 | China |